BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 22826352)

  • 1. Emerging methods for preparing iPS cells.
    Miyazaki S; Yamamoto H; Miyoshi N; Takahashi H; Suzuki Y; Haraguchi N; Ishii H; Doki Y; Mori M
    Jpn J Clin Oncol; 2012 Sep; 42(9):773-9. PubMed ID: 22826352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors.
    Kim JB; Zaehres H; Wu G; Gentile L; Ko K; Sebastiano V; Araúzo-Bravo MJ; Ruau D; Han DW; Zenke M; Schöler HR
    Nature; 2008 Jul; 454(7204):646-50. PubMed ID: 18594515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells.
    Tiemann U; Sgodda M; Warlich E; Ballmaier M; Schöler HR; Schambach A; Cantz T
    Cytometry A; 2011 Jun; 79(6):426-35. PubMed ID: 21548079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.
    Zhou W; Freed CR
    Stem Cells; 2009 Nov; 27(11):2667-74. PubMed ID: 19697349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia and TP53 deficiency for induced pluripotent stem cell-like properties in gastrointestinal cancer.
    Hoshino H; Nagano H; Haraguchi N; Nishikawa S; Tomokuni A; Kano Y; Fukusumi T; Saito T; Ozaki M; Sakai D; Satoh T; Eguchi H; Sekimoto M; Doki Y; Mori M; Ishii H
    Int J Oncol; 2012 May; 40(5):1423-30. PubMed ID: 22293932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of pluripotency-associated genes in mouse embryonic fibroblasts by non-viral transfection with in vitro-derived mRNAs encoding Oct4, Sox2, Klf4 and cMyc.
    Tavernier G; Wolfrum K; Demeester J; De Smedt SC; Adjaye J; Rejman J
    Biomaterials; 2012 Jan; 33(2):412-7. PubMed ID: 21993235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells.
    Tsai SY; Clavel C; Kim S; Ang YS; Grisanti L; Lee DF; Kelley K; Rendl M
    Stem Cells; 2010 Feb; 28(2):221-8. PubMed ID: 20014278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of reprogramming efficiency between transduction of reprogramming factors, cell-cell fusion, and cytoplast fusion.
    Hasegawa K; Zhang P; Wei Z; Pomeroy JE; Lu W; Pera MF
    Stem Cells; 2010 Aug; 28(8):1338-48. PubMed ID: 20572011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous KLF4 expression in human fetal endothelial cells allows for reprogramming to pluripotency with just OCT3/4 and SOX2--brief report.
    Ho PJ; Yen ML; Lin JD; Chen LS; Hu HI; Yeh CK; Peng CY; Lin CY; Yet SF; Yen BL
    Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1905-7. PubMed ID: 20689077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprogramming of mouse renal tubular epithelial cells to induced pluripotent stem cells.
    Wang WW; Wang W; Jiang Y; Han GF; Lu S; Li G; Zhang J
    Cytotherapy; 2013 May; 15(5):578-85. PubMed ID: 23415920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse induced pluripotent stem cells.
    Geoghegan E; Byrnes L
    Int J Dev Biol; 2008; 52(8):1015-22. PubMed ID: 18956334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced pluripotent stem cells.
    Zaehres H; Kim JB; Schöler HR
    Methods Enzymol; 2010; 476():309-25. PubMed ID: 20691874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes.
    Aasen T; Raya A; Barrero MJ; Garreta E; Consiglio A; Gonzalez F; Vassena R; Bilić J; Pekarik V; Tiscornia G; Edel M; Boué S; Izpisúa Belmonte JC
    Nat Biotechnol; 2008 Nov; 26(11):1276-84. PubMed ID: 18931654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More synergetic cooperation of Yamanaka factors in induced pluripotent stem cells than in embryonic stem cells.
    Huang J; Chen T; Liu X; Jiang J; Li J; Li D; Liu XS; Li W; Kang J; Pei G
    Cell Res; 2009 Oct; 19(10):1127-38. PubMed ID: 19736564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of clinically relevant "induced pluripotent stem" (iPS) cells.
    Heffernan C; Sumer H; Verma PJ
    J Stem Cells; 2011; 6(3):109-27. PubMed ID: 23264997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced pluripotent stem (iPS) cell research overview.
    Liu SP; Fu RH; Huang YC; Chen SY; Chien YJ; Hsu CY; Tsai CH; Shyu WC; Lin SZ
    Cell Transplant; 2011; 20(1):15-9. PubMed ID: 20887681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of p53-deficient induced pluripotent stem cells from mouse embryo fibroblasts.
    Alexandrova EM; Moll UM
    Methods Mol Biol; 2013; 962():157-64. PubMed ID: 23150445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53.
    Takenaka C; Nishishita N; Takada N; Jakt LM; Kawamata S
    Exp Hematol; 2010 Feb; 38(2):154-62. PubMed ID: 19922768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of pluripotency: from mouse to human.
    Zaehres H; Schöler HR
    Cell; 2007 Nov; 131(5):834-5. PubMed ID: 18045526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Induction and characterization of induced pluripotent stem (iPS) cells: a review].
    Cheng D; Lei L; Lu Z; Li Z; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2010 Apr; 26(4):421-30. PubMed ID: 20575428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.